Search

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

Biosimilar Candidate to Humira® Accepted For Review | BI US

Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom

New Platform: Unbridle Your Potential | Boehringer Ingelheim US

Read more on the Boehringer Ingelheim brand platform: Unbridle Your Potential, aimed at providing support and leadership for the equine industry.

Boehringer Ingelheim Announces the Launch of Centragard™ (eprinomectin and praziquantel transdermal solution), Innovative Internal Parasite Protection For Cats

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Coliform Mastitis: the facts to know | Boehringer Ingelheim US

Click here to learn more about different management practices that can help you to improve your dairy herd's bottom line and productivity.

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers